Chemotherapy for urothelial cancer is commonly associated with a poor survival rate. Recently, a combination of enfortumab vedotin (EV) and pembrolizumab treatment has achieved a better objective response rate (ORR) in a clinical trial and received accelerated approval from the USFDA for treating patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Now, a more extensive study with 886 patients with la/mUC compared the efficacy of EV + pembrolizumab with platinum-based chemotherapy (gemcitabine + cisplatin or carboplatin). A 21-day treatment with EV + pembrolizumab improved overall survival (31.5 vs. 16.1 months) and progression-free survival (12.5 vs.
6.3 months) in patients compared to platinum-based chemotherapy. Additionally, more patients treated with EV + pembrolizumab experienced shrinkage of cancer (68% vs. 44%) and complete response (29.1% vs. 12.5%). This…
